Please add email@example.com to your safe senders list.
|Support SITC Membership Meetings About SITC www.sitcancer.org|
March 2016 – In this Issue
A Message from the President
As we come to a close on the first quarter of 2016, I continue to be amazed by the number of people and organizations that have come together in order to increase the knowledge and reach of cancer immunotherapy. In response to the unprecedented needs in the field, the Society of Immunotherapy of Cancer (SITC) has continued its commitment to cancer immunotherapy education, and has increased its involvement cancer immunotherapy education programs worldwide.
As the world’s leading member-driven society dedicated to professionals working in the field of cancer immunotherapy, we work hard to ensure all of our members—students, clinicians, scientists, nurses, pharmacists, industry professionals and government representatives alike—have access to and are engaged in the implementation of timely, cutting-edge translational clinical research in cancer immunotherapy.
We at SITC look forward to working with others in the field through education, events and continued collaboration. On behalf of the society, I thank you for your efforts to advance the cancer immunotherapy field. Together, we can one day make the word “cure” a reality for cancer patients everywhere.
Howard L. Kaufman, MD, FACS
2016 NCI Immunotherapy Fellowship - Deadline Extended!
is pleased to announce the extension of the National Cancer Institute
(NCI) Immunotherapy Fellowship application deadline. Applications will
be accepted now through April 21, 2016.
This training program is designed for physicians who have completed a medical oncology fellowship program in the United States and who seek specialized training in immunotherapy with clinical trials and clinical trial development. The 1-year program at the CCR in Bethesda, Maryland, allows the fellow to have exposure to multiple clinical immunotherapeutic approaches, and also to key opinion leaders in the field of clinical immunotherapy. In addition, the fellowship provides opportunities to understand how to design, write, and run clinical trials, how to treat patients, how to manage toxicities, as well as opportunities to work with multiple experimental agents.Get more information, including eligibility requirements, here.
Radiation and Immunotherapy Leadership Summit
Thursday, March 31, 2016 • 9 a.m. – 5 p.m.
This free, one-day summit is intended for leaders in the fields of radiation, immunotherapy and combination treatments. The goal of this meeting is to discuss provocative questions surrounding the use of radiation and immunotherapy, in order to build consensus that generates a white paper report of recommendations and focus areas. Learn more and register here.
Immunotherapy Biomarkers 2016: Overcoming the Barriers
Friday, April 1, 2016 • 8 a.m. – 5 p.m.
from academia, biotech, pharma, government, researchers, and early
career scientists have the opportunity to hear updates on the immune
biomarker research, review the state of the art, explore current hurdles
to further success and consider recommendations during this one day
scientific program. Through
didactic sessions and panel discussions, SITC Immune Biomarkers Task
Force working group members and National Cancer Institute Center for
Cancer Research faculty will facilitate scientific exchange and solicit
stakeholder participation to promote successful immune biomarker
research. Learn more about the program and register here before the March 24 deadline.
Other Upcoming Collaborative Programs
Find more information on these and other collaborative programs here.
Two Locations Now Open for Registration
Part of the Advances in Cancer ImmunotherapyTM series, Cancer Immunotherapy 101 is an introductory, CME- and CE-certified program designed to provide clinical oncologists, nurses, pharmacists, and the entire team involved in treating cancer patients a greater understanding of cancer immunotherapies, their therapeutic effectiveness, and the appropriate selection and management of patients.
Mark your calendars for the upcoming SITC 31st Annual Meeting & Associated Programs! Known as the premier destination for scientific exchange, education and networking in the cancer immunotherapy field, this is the conference you don't want to miss. Look for an email in April for information on abstract submission dates, housing, registration, exhibiting and more! Click here to learn more.
31st Annual Meeting & Associated Programs will include:
Not a member yet? Join today!
SITC is the world’s leading member-driven society dedicated to professionals working in the field of cancer immunotherapy. As a member, you will join a growing network of nearly 1,300 basic and translational scientists, practitioners, healthcare professionals, government leaders, and industry professionals worldwide.
There are several membership categories including: Regular, Affiliate, Allied Health, Emeritus, Nurse and Physician Extender, Patient and Patient Advocate, Pharmacist, and Scientist-in-Training/Student memberships. To learn more about these categories, and to apply, visit the Membership page.
Membership Benefits Include:
New members often join SITC because a current member has invited them.
Please encourage your colleagues, including nurses, pharmacists, and
students, to become official SITC members by sending personalized
invitations with our online tool or have the people you invite list your name on their membership applications. If each SITC member recruits two others, we could quickly grow to 3,000 members!
Publications & Resources
Society for Immunotherapy of Cancer (SITC)
© 2016 Society for Immunotherapy of Cancer
Join us on:
If you do not wish to be included in our mailing list, please forward this message to firstname.lastname@example.org with the word "Remove" in the subject line.
Please add email@example.com to your safe senders list.